Drug intelligence / Profile preview

WLH-130

Development stage: Preclinical
Lead developer: Wanle Pharmaceutical
Modality: Small Molecules

Overview

WLH-130 is a small molecule chemotherapy agent currently in development by Wanle Pharmaceutical. It is part of the company's oncology pipeline, which focuses on a broad range of malignancies including bladder cancer, breast cancer, hematologic malignancies (leukemia and lymphoma), liver cancer, and digestive system cancers such as gastric and colorectal cancer. As a chemotherapy drug, it likely functions by inhibiting cell division or inducing apoptosis in rapidly dividing cancer cells, although its specific molecular target and mechanism of action have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on WLH-130.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WLH-130.

Explore the full profile